Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions

被引：2
作者：
He, Weishan [1 ]
Zheng, Donglin [2 ]
Deng, Guangmei [1 ]
Liu, Wenya [1 ]
Wu, Fasheng [2 ]
Chen, Jibing [2 ]
机构：
[1] Guangxi Univ Chinese Med, Grad Sch, Nanning, Guangxi, Peoples R China
[2] Guangxi Univ Chinese Med, Ruikang Hosp, Nanning, Guangxi, Peoples R China
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 05期
关键词：
Radiotherapy; Immunotherapy; Immune checkpoint inhibitor; Immunoradiotherapy; Non-small-cell lung cancer; PLAYER; PSGL-1;
D O I：
10.1007/s12094-023-03337-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small-cell lung cancer (NSCLC) has an extremely low 5-year survival rate, with the only effective treatment being immunoradiotherapy (iRT). Here, we review the progress of clinical research on iRT for non-small-cell lung cancer (NSCLC) over 2018-2023, as well as the future directions. We first discuss the synergistic mechanisms of iRT, reflected in three aspects: immune regulation of RT, RT-activated immune-related pathways, and RT-related immune sensitization. iRT may include either external-beam or stereotactic-body RT combined with either immune checkpoint inhibitors (e.g., immunoglobulins against immune programmed cell death (PD) 1/PD ligand 1 or CD8+ T lymphocyte antigen 4) or traditional Chinese medicine drugs. Regarding clinical effectiveness and safety, iRT increases overall and progression-free survival and tumor control rate among patients with NSCLC but without a considerable increase in toxicity risk. We finally discuss iRT challenges and future directions reported over 2018-2023.
引用
收藏
页码：1063 / 1076
页数：14
相关论文
共 92 条
  • [71] Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
    Theelen, Willemijn S. M. E.
    Peulen, Heike M. U.
    Lalezari, Ferry
    van der Noort, Vincent
    de Vries, Jeltje F.
    Aerts, Joachim G. J. V.
    Dumoulin, Daphne W.
    Bahce, Idris
    Niemeijer, Anna-Larissa N.
    de Langen, Adrianus J.
    Monkhorst, Kim
    Baas, Paul
    [J]. JAMA ONCOLOGY, 2019, 5 (09) : 1276 - 1282
  • [72] Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
    Tian, Lin
    Goldstein, Amit
    Wang, Hai
    Lo, Hin Ching
    Kim, Ik Sun
    Welte, Thomas
    Sheng, Kuanwei
    Dobrolecki, Lacey E.
    Zhang, Xiaomei
    Utluri, Nagireddy P.
    Hung, Thuy L. P.
    Mani, Sendurai A.
    Stossi, Fabio
    Sreekumar, Arun
    Mancini, Michael A.
    Decker, William K.
    Zong, Chenghang
    Lewis, Michael T.
    Zhang, Xiang H. -F.
    [J]. NATURE, 2017, 544 (7649) : 250 - +
  • [73] Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
    Twyman-Saint Victor, Christina
    Rech, Andrew J.
    Maity, Amit
    Rengan, Ramesh
    Pauken, Kristen E.
    Stelekati, Erietta
    Benci, Joseph L.
    Xu, Bihui
    Dada, Hannah
    Odorizzi, Pamela M.
    Herati, Ramin S.
    Mansfield, Kathleen D.
    Patsch, Dana
    Amaravadi, Ravi K.
    Schuchter, Lynn M.
    Ishwaran, Hemant
    Mick, Rosemarie
    Pryma, Daniel A.
    Xu, Xiaowei
    Feldman, Michael D.
    Gangadhar, Tara C.
    Hahn, Stephen M.
    Wherry, E. John
    Vonderheide, Robert H.
    Minn, Andy J.
    [J]. NATURE, 2015, 520 (7547) : 373 - +
  • [74] Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers
    Vanpouille-Box, Claire
    Formenti, Silvia C.
    Demaria, Sandra
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (02) : 259 - 265
  • [75] Positive Role of Chinese Herbal Medicine in Cancer Immune Regulation
    Wang, Sumei
    Long, Shunqin
    Deng, Zhiyin
    Wu, Wanyin
    [J]. AMERICAN JOURNAL OF CHINESE MEDICINE, 2020, 48 (07): : 1577 - 1592
  • [76] Antitumor effects of immunity-enhancing traditional Chinese medicine
    Wang, Yeshu
    Zhang, Qunfang
    Chen, Yuchao
    Liang, Chun-Ling
    Liu, Huazhen
    Qiu, Feifei
    Dai, Zhenhua
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
  • [77] Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Respons
    Welsh, James W.
    Tang, Chad
    de Groot, Patricia
    Naing, Aung
    Hess, Kenneth R.
    Heymach, John V.
    Papadimitrakopoulou, Vassiliki A.
    Cushman, Taylor R.
    Subbiah, Vivek
    Chang, Joe Y.
    Simon, George R.
    Ramapriyan, Rishab
    Barsoumian, Hampartsoum B.
    Menon, Hari
    Cortez, Maria Angelica
    Massarelli, Erminia
    Quynh Nguyen
    Sharma, Padmanee
    Allison, James P.
    Diab, Adi
    Verma, Vivek
    Raju, Uma
    Shaaban, Sherif G.
    Dadu, Ramona
    Cabanillas, Maria E.
    Wang, Kelvin
    Anderson, Clark
    Gomez, Daniel R.
    Hahn, Stephen
    Komaki, Ritsuko
    Hong, David S.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2019, 7 (12) : 1903 - 1909
  • [78] Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
    Wirsdoerfer, Florian
    de Leve, Simone
    Jendrossek, Verena
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (01)
  • [79] Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After
    Woody, Susan
    Hegde, Aparna
    Arastu, Hyder
    Peach, M. Sean
    Sharma, Nitika
    Walker, Paul
    Ju, Andrew W.
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [80] Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
    Wu, Leilei
    Zhang, Zhenshan
    Bai, Menglin
    Yan, Yujie
    Yu, Jinming
    Xu, Yaping
    [J]. CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
12345678910